PL1917026T3 - Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom - Google Patents

Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom

Info

Publication number
PL1917026T3
PL1917026T3 PL06776572T PL06776572T PL1917026T3 PL 1917026 T3 PL1917026 T3 PL 1917026T3 PL 06776572 T PL06776572 T PL 06776572T PL 06776572 T PL06776572 T PL 06776572T PL 1917026 T3 PL1917026 T3 PL 1917026T3
Authority
PL
Poland
Prior art keywords
tissue factor
lipidated tissue
antihemorrhagic agent
topical
topical antihemorrhagic
Prior art date
Application number
PL06776572T
Other languages
English (en)
Polish (pl)
Inventor
Egea Javier Pedreño
Catas S Luis Caveda
Original Assignee
Thrombotargets Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe S L filed Critical Thrombotargets Europe S L
Publication of PL1917026T3 publication Critical patent/PL1917026T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
PL06776572T 2005-08-03 2006-08-02 Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom PL1917026T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380179A EP1749536A1 (fr) 2005-08-03 2005-08-03 Stimulateurs activés du Facteur X et leur utilisation en tant qu'agents anti-hemorragiques pour l'usage topique
PCT/EP2006/007660 WO2007014771A1 (fr) 2005-08-03 2006-08-02 Stimulateurs de facteur x active (fxa) utilises en tant que nouveaux agents antihemorragiques topiques
EP06776572.7A EP1917026B9 (fr) 2005-08-03 2006-08-02 Facteur tissulaire lipidé pour son utilisation en tant qu'agent antihemorragique topique

Publications (1)

Publication Number Publication Date
PL1917026T3 true PL1917026T3 (pl) 2014-08-29

Family

ID=35916272

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776572T PL1917026T3 (pl) 2005-08-03 2006-08-02 Lipidowany czynnik tkankowy do stosowania jako środek do miejscowego zapobiegania krwotokom

Country Status (13)

Country Link
EP (3) EP1749536A1 (fr)
JP (2) JP5268638B2 (fr)
KR (1) KR101362993B1 (fr)
CN (1) CN101291686B (fr)
AU (1) AU2006274979B2 (fr)
BR (1) BRPI0616535B8 (fr)
CA (1) CA2617534C (fr)
DK (1) DK1917026T3 (fr)
ES (1) ES2468225T3 (fr)
HK (1) HK1119569A1 (fr)
PL (1) PL1917026T3 (fr)
TW (2) TWI441645B (fr)
WO (2) WO2007014771A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772371B2 (en) * 2005-08-03 2010-08-10 Thrombotargets Corporation Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
EP2745852A1 (fr) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Compositions d'agent d'étanchéité
EP2759305A1 (fr) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Compositions hémostatiques
CN110133303B (zh) * 2019-05-13 2023-04-07 深圳优迪生物技术有限公司 凝血酶原时间测定试剂及其应用
CN112433057B (zh) * 2020-11-10 2023-06-09 北京美创新跃医疗器械有限公司 一种狼疮抗凝物的筛选试剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
ATE120645T1 (de) * 1986-11-04 1995-04-15 Genentech Inc Verfahren und therapeutische zubereitungen für die behandlung von gerinnungsstörungen.
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
US6239101B1 (en) * 1989-07-05 2001-05-29 Oklahoma Medical Research Foundation Thrombin binding polypeptides
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
WO1993009804A1 (fr) * 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
US5441759A (en) * 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
EP0833911B1 (fr) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Anticorps contre la thromboplastine tissulaire comportant des regions de determination complementaire greffees et leurs methodes d'utilisation
WO2000004148A1 (fr) * 1998-07-15 2000-01-27 Genentech, Inc. Variantes de proteines de facteurs tissulaires presentant une affinite accrue pour le facteur de coagulation fvii/fviia
EP1051620B1 (fr) * 1998-10-30 2006-06-07 Jonathan L. Miller Regions variables de chaine lourde et de chaine legere d'anticorps diriges contre la glycoproteine plaquettaire humaine ib alpha
WO2002030479A1 (fr) 2000-10-13 2002-04-18 On Site Gas Systems, Inc. Bandage utilisant des tamis moleculaires
US7015193B2 (en) * 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004039842A2 (fr) * 2002-10-31 2004-05-13 Novo Nordisk A/S Anticorps humanises anti-facteur tissulaire
CN101014711A (zh) * 2004-06-25 2007-08-08 阿尔特生物科学公司 植物中组织因数的制造

Also Published As

Publication number Publication date
JP5268638B2 (ja) 2013-08-21
WO2007014771A1 (fr) 2007-02-08
AU2006274979A1 (en) 2007-02-08
BRPI0616535A2 (pt) 2011-06-21
KR101362993B1 (ko) 2014-02-21
JP2009503008A (ja) 2009-01-29
TW200744633A (en) 2007-12-16
CN101291686B (zh) 2013-03-13
CA2617534A1 (fr) 2007-02-08
EP1915175A2 (fr) 2008-04-30
EP1917026A1 (fr) 2008-05-07
BRPI0616535B8 (pt) 2021-05-25
TW200744628A (en) 2007-12-16
TWI441645B (zh) 2014-06-21
AU2006274979B2 (en) 2012-12-13
EP1749536A1 (fr) 2007-02-07
DK1917026T3 (da) 2014-06-10
BRPI0616535B1 (pt) 2019-11-12
EP1917026B9 (fr) 2014-06-18
WO2007014772A2 (fr) 2007-02-08
JP2009503009A (ja) 2009-01-29
HK1119569A1 (en) 2009-03-13
ES2468225T3 (es) 2014-06-16
CN101291686A (zh) 2008-10-22
CA2617534C (fr) 2016-07-05
KR20080043324A (ko) 2008-05-16
WO2007014772A3 (fr) 2007-04-12
EP1917026B1 (fr) 2014-03-05
ES2468225T9 (es) 2014-10-24

Similar Documents

Publication Publication Date Title
TWI366469B (en) Emulsified skin agent for external use
HK1122991A1 (en) External preparation for skin
IL186871A0 (en) External preparation for skin
ZA200803150B (en) Topical Formulations
ZA200800006B (en) Composition for treating skin lesions
GB2430884B (en) Compositions for topical treatment
EP1938808A4 (fr) Préparation à usage externe.
HK1119569A1 (en) Lipidated tissue factor for use as topical antihemorrhagic agent
EP1854354A4 (fr) Agent destine a ameliorer un pouvoir antiseptique
GB2416693B (en) Composition for reducing blood lipids
EP1957080A4 (fr) Formulations de glucocorticosteroide locales
EP1895843A4 (fr) Formules topiques de micogel
ZA200605597B (en) Compositions for use with skin
GB0516610D0 (en) Compounds for use in therapy
ZA201003835B (en) Therapeutic agent for ulcer
AU3435P (en) Kakegawa S63 Calibrachoa hybrid
AU3279P (en) USCALI11 Calibrachoa hybrid
AU3233P (en) Balcabpurp Calibrachoa hybrid
AU3280P (en) USCALI4 Calibrachoa hybrid
AU3238P (en) Balcabred Calibrachoa hybrid
AU3236P (en) Balcabrose Calibrachoa hybrid
AU3235P (en) Balcabwite Calibrachoa hybrid
AU3281P (en) USCALI28 Calibrachoa hybrid
AU3234P (en) Balcabcher Calibrachoa hybrid
GB0517519D0 (en) Topical prostaglandin formulation